✦ LIBER ✦

Disease recurrence after intraarterial chemotherapy in 2 patients with adenoid cystic carcinoma of lacrimal gland

✍ Scribed by Fellman, Melissa; Carter, Keith; Call, Conley B.; Esmaeli, Bita

Book ID: 122866699
Publisher: Canadian Ophthalmological Society
Year: 2013
Tongue: English
Weight: 109 KB
Volume: 48
Category: Article
ISSN: 0008-4182
DOI: 10.1016/j.jcjo.2012.09.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Analysis of the Effect of Intra

Clinical Analysis of the Effect of Intraarterial Cytoreductive Chemotherapy in the Treatment of Lacrimal Gland Adenoid Cystic Carcinoma

✍ David T. Tse; Pasquale Benedetto; Sander Dubovy; Joyce C. Schiffman; William J. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 468 KB

Microdissection Genotyping Analysis of t

Microdissection Genotyping Analysis of the Effect of Intraarterial Cytoreductive Chemotherapy in the Treatment of Lacrimal Gland Adenoid Cystic Carcinoma

✍ David T. TSE; Sydney D. Finkelstein; Pasquale Benedetto; Sander Dubovy; Joyce Sc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 483 KB

Long-term local control of recurrent ade

Long-term local control of recurrent adenoid cystic carcinoma in the parotid gland with radiotherapy and intraarterial infusion chemotherapy

✍ Terashima, Koutarou ;Shioyama, Yoshiyuki ;Nakamura, Katsumasa ;Ohga, Saiji ;Nomo 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 320 KB

The effect of menatetrenone, a vitamin K

The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment : A pilot study

✍ Toshihiko Mizuta; Iwata Ozaki; Yuichiro Eguchi; Tsutomu Yasutake; Seiji Kawazoe; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

A phase 2 trial of bortezomib followed b

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303)

✍ Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S. Axelrod; Ron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. ## METHODS: Eligibility criteria included incurable ACC, any number of pr